Sign in Subscribe
Biotechnology industries

Seattle Genetics and MedImmune Collaborate on Antibody-Drug Conjugate Technology

Strategic Insights

— 1 min read

Seattle Genetics, Inc. (SGEN) has partnered with MedImmune, Inc. to develop and commercialize antibody-drug conjugate (ADC) products. Under the collaboration, MedImmune will utilize Seattle Genetics' ADC technology to target a specific tumor target and pay an upfront fee of $2.0 million. MedImmune also has the option to access the ADC technology for a second proprietary antibody program. The collaboration will focus on researching, developing, manufacturing, and commercializing ADC products, with Seattle Genetics receiving payment for its assistance and research support.

Key Takeaways:

  • Seattle Genetics and MedImmune have formed a collaboration to develop and commercialize ADC products using Seattle Genetics' technology.
  • MedImmune will pay an upfront fee of $2.0 million for rights to utilize Seattle Genetics' ADC technology for a single tumor target.
  • MedImmune has an option to access the ADC technology for a second proprietary antibody program, in addition to the upfront fee.
  • The collaboration will result in progress-dependent milestone payments and royalties on net sales of ADC products.
  • Seattle Genetics will receive material supply and annual maintenance fees, as well as research support payments for assistance provided.
  • ADC technology utilizes synthetic, highly potent drugs attached to antibodies through proprietary linker systems, designed to spare non-target cells from toxic effects.
  • This collaboration highlights the potential of ADC technology to increase cell-killing activity of antibodies, with the goal of treating cancer and other human diseases.
  • Seattle Genetics discovers and develops monoclonal antibody-based therapeutics, focusing on cancer and other human diseases.

Statistics:

  • Seattle Genetics' ADC technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems.
  • The linkers are designed to be stable in the bloodstream but release the drug payload under specific conditions, potentially sparing non-target cells harmful effects.
  • The ADC technology targets specific cells through monoclonal antibodies, increasing cell-killing activity.
  • Seattle Genetics will receive $2.0 million upfront, as well as material supply and annual maintenance fees, and research support payments.
  • The collaboration will involve researching, developing, manufacturing, and commercializing ADC products.

Sources:

  • Seattle Genetics, Inc. (SGEN)
  • MedImmune, Inc.
  • Health & Medicine Week editors, (2005), Copyright 2005, Health & Medicine Week via NewsRx.com

Read more